Enanta Pharmaceuticals | ENTA - Sales Revenues


Enanta Pharmaceuticals reported $16.96M in Sales Revenues for its fiscal quarter ending in December of 2024.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 73.74M 190.29M Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.25B 30M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.27B 240M Mar/2026
Insmed USD 305.96M 42.16M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
J&J USD 24.1B 500M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
Merck USD 16.29B 110M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026